Cryoport, Inc. reported first‑quarter 2026 revenue of $47.8 million, a 16% year‑over‑year increase that beat the consensus estimate of $44.87 million. The top‑line growth was driven by a 26% rise in commercial cell and gene therapy (CGT) revenue to $9.1 million and an 18% increase in clinical trial support revenue to $12.9 million, underscoring the company’s expanding role in the CGT supply chain.
Gross margin improved to 45.8% from 45.4% in the prior year, while the Life Sciences Products segment’s margin slipped slightly from 42.3% to 41.9% due to a mix shift toward lower‑margin cryogenic systems. Adjusted EBITDA moved closer to profitability, rising $2.2 million year‑over‑year to a negative $0.6 million, a significant improvement over the $1.5 million loss reported in Q1 2025.
The company’s EPS of $-0.25 missed the consensus estimate of $-0.22 by $0.03, reflecting the continued impact of higher operating costs and the absence of one‑time gains. Despite the EPS miss, the revenue beat and margin improvement signal strong demand and effective cost management in key growth areas.
Cryoport raised its full‑year 2026 revenue guidance to $192 million–$196 million, up from the previous $190 million–$194 million range. CEO Jerrell Shelton said, "Our first quarter results continue to demonstrate our market‑leading position as revenue was $47.8 million, up 16% year‑over‑year, which puts us off to a very strong start for the year." He added, "Reflecting on our strong performance for the first quarter and our increased visibility into the remainder of the year, we are raising our full‑year revenue guidance to $192 million to $196 million."
Shelton also noted, "We also believe that based on our progress year‑to‑date, we will achieve positive adjusted EBITDA in the second half of this year." He highlighted a milestone for the company’s client, Rocket Pharmaceutical, which received FDA accelerated approval for its gene therapy, KRESLADI, increasing the number of commercial therapies Cryoport supports to 21.
The guidance lift reflects management’s confidence in sustained demand for Cryoport’s integrated temperature‑controlled supply chain services and the expansion of its global footprint, including new supply‑chain centers in Paris and Santa Ana. The company’s focus on scaling its Life Sciences Services and Products segments, coupled with strategic investments in cryogenic technology, positions it to capture a larger share of the growing CGT market.
Overall, Cryoport’s Q1 results demonstrate a solid top‑line trajectory and a narrowing loss, while the EPS miss highlights the need for continued cost discipline as the company scales its operations. The raised revenue guidance signals management’s optimism about the second half of 2026 and the broader CGT supply‑chain landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.